Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

MOR-201 program discontinued in Q2 at MorphoSys

Aug. 4, 2003

Neovascular targeting therapy developed at Munich Biotech

Aug. 1, 2003

New phase II trial studies of Genasense in combination with rituximab/fludarabine for CLL

Aug. 1, 2003

Aventis and ImmunoGen combine forces to develop anticancer therapeutics

Aug. 1, 2003

Human breast cancer growth inhibited by nocturnal melatonin

July 31, 2003

Evidence of antitumor effects of DMXAA in refractory solid tumors

July 31, 2003

Additive antitumor effects described for SU-5416 and dalteparin in a glioblastoma cell line

July 31, 2003

Feasibility of PACT approach to solid tumor therapy demonstrated using CVS-10290

July 30, 2003

Potential chemopreventive agents in development at SRI

July 30, 2003

Telomerase inhibitor GRN-163 advances through preclinical testing

July 29, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...